Correction
- PMID: 30287312
- DOI: 10.1016/j.jaad.2018.09.046
Correction
Erratum for
-
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).J Am Acad Dermatol. 2017 Nov;77(5):855-862. doi: 10.1016/j.jaad.2017.06.153. Epub 2017 Sep 13. J Am Acad Dermatol. 2017. PMID: 28917383 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources